Comparative Pharmacology

Head-to-head clinical analysis: MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5 AND SODIUM CHLORIDE 0 9 IN PLASTIC CONTAINER.

Peer-Reviewed Evidence

Differential Analysis

MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER vs POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.

MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER

Electrolyte

Category C

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

Electrolyte

Category A/B

Head-to-Head

Clinical Matrix

Mechanism of Action

Magnesium sulfate provides magnesium ions, which are essential for various physiological processes. It acts as a cofactor for enzymatic reactions, stabilizes excitable membranes, and antagonizes calcium entry at the neuromuscular junction, leading to reduced acetylcholine release and muscle relaxation. In the CNS, it may act as a noncompetitive antagonist of NMDA receptors, exerting anticonvulsant effects.

Potassium is the major intracellular cation; it maintains cellular membrane potential, acid-base balance, and fluid balance. Dextrose provides caloric supplementation; sodium chloride provides sodium and chloride ions for electrolyte balance.

Clinical Dosing

1 to 4 g intravenously as a 5% to 20% solution, rate not exceeding 150 mg/min; dosing frequency depends on indication (e.g., preeclampsia/eclampsia: 4-5 g IV loading then 1-2 g/hr infusion; hypomagnesemia: 1-2 g IV over 1-2 hours, may repeat based on serum magnesium levels).

40 mEq potassium chloride intravenously, administered at a rate not exceeding 10 mEq/hour and a concentration no greater than 40 mEq/L. For severe hypokalemia, may be infused at up to 20 mEq/hour with continuous ECG monitoring.

Direct Interaction

None Documented